20 May 2012
Poster Highlights
Summaries of the most important references in cancer and thrombosis selected by the Steering Committee are provided and available for download.
|
Hypercoagulability and tissue factor gene upregulation in hematologic malignanciesFalanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. Mar 2008;34(2):204-210. Falanga A, Barbui T, Rickles FR. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. Mar 2008;34(2):204-210.
 Download PDF |
Preview
Download PDF
|
Inhibition of tissue factor signaling suppresses tumor growthVersteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. Jan 1 2008;111(1):190-199. Versteeg HH, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. Jan 1 2008;111(1):190-199.
Download PDF |
|
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancerMeyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch I Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch I
Download PDF |
|
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patientsCarrier M, Lee AY, Bates SM, Anderson DR, Wells PS. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res. 2008;123(1):177-183. Carrier M, Lee AY, Bates SM, Anderson DR, Wells PS. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res. 2008;123(1):177-183.
Download PDF |
|
The effect of low molecular weight heparin on survival in patients with advanced malignancyKlerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. Apr 1 2005;23(10):2130-2135. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. Apr 1 2005;23(10):2130-2135.
Download PDF |
|
Incidence of venous thromboembolism in patients hospitalized with cancerStein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. Jan 2006;119(1):60-68. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. Jan 2006;119(1):60-68.
Download PDF |
|
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. May 15 2004;22(10):1944-1948. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. May 15 2004;22(10):1944-1948.
Download PDF |
|
The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolismSorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. Apr 23 1998;338(17):1169-1173. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. Apr 23 1998;338(17):1169-1173.
Download PDF |
|
Phlegmasia alba dolensTrousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865;3 (94). Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. 1865;3 (94).
Download PDF |
|
A clinical outcome-based perspective study on venous thromboembolism after cancer surgery: The @RISTOS ProjectAgnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. Jan 2006;243(1):89-95. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. Jan 2006;243(1):89-95.
Download PDF |
|
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerBergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. Mar 28 2002;346(13):975-980. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. Mar 28 2002;346(13):975-980.
Download PDF |
|
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerLee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M for the CLOT Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M for the CLOT Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with
Download PDF |
|
Deep-vein thrombosis and the incidence of subsequent symptomatic cancerPrandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. Oct 15 1992;327(16):1128-1133. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. Oct 15 1992;327(16):1128-1133.
Download PDF |
|
Incidence of venous thromboembolism in patients hospitalized with cancerStein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. Jan 2006;119(1):60-68. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. Jan 2006;119(1):60-68.
Download PDF |
© Copyright 2008-2012. All Rights Reserved.